How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

214 results for

Cantharidin

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Topical Cantharidin/ Salicylic Acid/ Podophyllin for the Treatment of Warts: Clinical Effectiveness and Guidelines

Topical Cantharidin/ Salicylic Acid/ Podophyllin for the Treatment of Warts: Clinical Effectiveness and Guidelines Topical Cantharidin/ Salicylic Acid/ Podophyllin for the Treatment of Warts: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Topical Cantharidin/ Salicylic Acid/ Podophyllin for the Treatment of Warts: Clinical Effectiveness and Guidelines Topical Cantharidin/ Salicylic Acid/ Podophyllin for the Treatment of Warts: Clinical Effectiveness (...) and Guidelines Last updated: January 21, 2019 Project Number: RA1006-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the comparative clinical effectiveness of topical cantharidin/salicylic acid/podophyllin versus other topical treatments for warts? What are the evidence-based guidelines for the topical treatment of warts? Key Message One non-randomized study and two evidence-based guidelines were identified regarding topical cantharidin/ salicylic acid

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

2. Disodium Cantharidinate and Vitamin B6 Injection Adjunct with Platinum-Based Chemotherapy for the Treatment of Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis. (PubMed)

Disodium Cantharidinate and Vitamin B6 Injection Adjunct with Platinum-Based Chemotherapy for the Treatment of Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis. Disodium cantharidinate and vitamin B6 (DCVB6) injection is effective and widely used for the clinical treatment of non-small-cell lung cancer (NSCLC). This meta-analysis aimed to provide evidence-based medical data for clinical treatment with DCVB6 injection.We searched 7 medical databases up to January 2018 for all randomized

Full Text available with Trip Pro

2019 Evidence-based Complementary and Alternative Medicine (eCAM)

3. A comparative study of topical cantharidin and intralesional PPD to treat molluscum contagiosum. (PubMed)

A comparative study of topical cantharidin and intralesional PPD to treat molluscum contagiosum. Background: The immune system plays an important part in the clearance of molluscum contagiosum (MC) and, therefore, there has lately been a trend in using immunotherapy in MC therapy. Tuberculin-purified protein derivatives (PPDs) and topical cantharidin have not earlier been compared with their effectiveness in therapy Aim: The aim of this research was to determine the effectiveness and security (...) of intralesional immunotherapy in the therapy of MC with tuberculin PPD versus topical cantharidin Patients and methods: Twenty patients with various MC lesions received topical cantharidin as control (group A) and 20 MC patients received intralesional tuberculin PPD following prior intradermal immunity tests (group B‏). Results: Complete clearance of lesions was detected in 90.0% of patients in the cantharidin group; the partial response was detected in10.0% of the patients. However, in the PPD group, 85

2019 Journal of Dermatological Treatment

4. Safety and efficacy of topical cantharidin for the treatment of pediatric molluscum contagiosum: a prospective, randomized, double-blind, placebo-controlled pilot trial. (PubMed)

Safety and efficacy of topical cantharidin for the treatment of pediatric molluscum contagiosum: a prospective, randomized, double-blind, placebo-controlled pilot trial. Topical cantharidin is a commonly used treatment for molluscum contagiosum (MC). However, studies validating its safety and efficacy are limited. We conducted a 6-week, randomized, double-blind, placebo-controlled trial with subsequent open-label extension to assess the safety and effectiveness of cantharidin in treating (...) pediatric MC. Ninety-four participants with MC were randomized to receive cantharidin or placebo, with or without occlusion. The primary outcome was complete lesion clearance. Secondary outcomes included post-treatment lesion count, adverse events, and side effects. No significant differences between the study arms, including baseline lesion count, were observed. The overall mean (SD) baseline lesion count was 22.2 (12.9). The number of participants achieving total clearance is as follows: 7/23 (30.4

2018 International Journal of Dermatology

5. Cantharidin is Superior to Trichloroacetic Acid for the Treatment of Non-mucosal Genital Warts: A Pilot Randomized Controlled Trial (PubMed)

Cantharidin is Superior to Trichloroacetic Acid for the Treatment of Non-mucosal Genital Warts: A Pilot Randomized Controlled Trial Condyloma Acuminatum is a sexually transmitted viral disease caused by the human papilloma virus (HPV). It is the most common viral sexually transmitted disease. In this randomized controlled trial, cantharidin was found to be more effective and better tolerated than trichloroacetic acid for the treatment of these lesions. Patients treated with cantharidin healed

Full Text available with Trip Pro

2018 Clinical and experimental obstetrics & gynecology

6. Role of cantharidin in the activation of IKKα/IκBα/NF-κB pathway by inhibiting PP2A activity in cholangiocarcinoma cell lines (PubMed)

Role of cantharidin in the activation of IKKα/IκBα/NF-κB pathway by inhibiting PP2A activity in cholangiocarcinoma cell lines Cantharidin (CAN), a potent inhibitor of serine/threonine‑protein phosphatase 2A (PP2A), is widely used in clinical practice, particularly in the treatment of advanced cancer due to its specific action on these types of cancer. In the present study, the inhibitory effect of CAN was examined in two cholangiocarcinoma cell lines (QBC939 and Hucc‑t1). Following

Full Text available with Trip Pro

2018 Molecular medicine reports

7. Cantharidin-encapsulated thermal-sensitive liposomes coated with gold nanoparticles for enhanced photothermal therapy on A431 cells (PubMed)

Cantharidin-encapsulated thermal-sensitive liposomes coated with gold nanoparticles for enhanced photothermal therapy on A431 cells Plasmonic nanostructure-mediated photothermal therapy (PTT) is a promising alternative therapy for the treatment of skin cancer and other diseases. However, the insufficient efficiency of PTT at irradiation levels tolerable to tissues and the limited biodegradability of nanomaterials are still crucial challenges. In this study, a novel nanosystem for PTT based (...) on liposome-nanoparticle assemblies (LNAs) was established.Thermal-sensitive liposomes (TSLs) encapsulating cantharidin (CTD) were coated with gold nanoparticles (GNPs) and used in near-infrared (NIR) illumination-triggered PTT and thermally induced disruption on A431 cells.The coated GNPs disintegrated into small particles of 5-6 nm after disruption of TSLs, allowing their clearance by the liver and kidneys. CTD encapsulated in the TSLs was released into cytoplasm after PTT. The released CTD increased

Full Text available with Trip Pro

2018 International journal of nanomedicine

8. Unique Responses of Hepatocellular Carcinoma and Cholangiocarcinoma Cell Lines toward Cantharidin and Norcantharidin (PubMed)

Unique Responses of Hepatocellular Carcinoma and Cholangiocarcinoma Cell Lines toward Cantharidin and Norcantharidin The present study aimed to investigate whether cell lines from human gastric and liver cancers respond differently toward cantharidin (CTD) and norcantharidin (NCTD) than other types of cancer cells. We first established the half maximal inhibitory concentrations (IC50s) of CTD for a large panel of cancer cell lines representing the 12 major types of human cancers and the mode

Full Text available with Trip Pro

2018 Journal of Cancer

9. Cantharidin and Occlusion in Verruca Epithelium

Cantharidin and Occlusion in Verruca Epithelium Cantharidin and Occlusion in Verruca Epithelium - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Cantharidin and Occlusion in Verruca Epithelium (COVE-1 (...) Consulting, Inc. Paidion Research, Inc. BioClinica, Inc. Information provided by (Responsible Party): Verrica Pharmaceuticals Inc. Study Details Study Description Go to Brief Summary: This is a Phase 2, open label study (Study number VP-102-105; referred to as COVE-1 [Cantharidin and Occlusion in Verruca Epithelium]) to evaluate the efficacy, safety and tolerability of VP-102 treatment in subjects with common warts. This study has two Cohorts. Condition or disease Intervention/treatment Phase Common Wart

2018 Clinical Trials

10. Cantharidin Inhibits Anti-Apoptotic Bcl-2 Family Proteins and Induces Apoptosis in Human Osteosarcoma Cell Lines MG-63 and MNNG/HOS via Mitochondria-Dependent Pathway (PubMed)

Cantharidin Inhibits Anti-Apoptotic Bcl-2 Family Proteins and Induces Apoptosis in Human Osteosarcoma Cell Lines MG-63 and MNNG/HOS via Mitochondria-Dependent Pathway BACKGROUND Cantharidin (CTD) is one of the major active ingredients of blister beetles and has significant antitumor activity in many cancer cell lines. The aim of our study was to evaluate the effect of CTD on the apoptosis of human osteosarcoma cells MG-63 and MNNG/HOS, and to explore the possible molecular mechanism. MATERIAL (...) , and CTD promoted cells apoptosis in a dose-dependent manner. In addition, cantharidin-induced apoptosis was accompanied by increased expression of Bax and PARP and decreased expression of Bcl-2, p-Akt, and p-Cdc2. CONCLUSIONS CTD accelerates the apoptosis of MG-63 and MNNG/HOS cells in a concentration-dependent manner through the mitochondria-dependent pathway, suggesting that use of CTD is a novel approach for the treatment of osteosarcoma.

Full Text available with Trip Pro

2018 Medical science monitor : international medical journal of experimental and clinical research

11. Efficacy and Safety of Topical Cantharidin Treatment for Molluscum Contagiosum and Warts: A Systematic Review. (PubMed)

Efficacy and Safety of Topical Cantharidin Treatment for Molluscum Contagiosum and Warts: A Systematic Review. Topical cantharidin is routinely used for the treatment of molluscum contagiosum and warts. The objective of this systematic review is to assess the efficacy and safety of topical cantharidin treatment for molluscum contagiosum and warts.We performed a systematic review of studies assessing topical cantharidin treatment of molluscum contagiosum or warts. We searched the databases (...) of Cochrane, EMBASE, GREAT, LILACS, MEDLINE, and Scopus. Two authors performed the study selection and data extraction.Twenty studies (1958-2018) met inclusion/exclusion criteria. Twelve studies assessed warts, and eight studies assessed molluscum contagiosum. Overall, 1752 patients were included (range 0.3-62 years; specified in 15 studies). Clearance rates with topical cantharidin for molluscum contagiosum were variable (range 15.4-100%). Significant clearance of warts with maintenance of clearance

2018 American journal of clinical dermatology

12. Morning blisters: cantharidin-related Meloidae burns. (PubMed)

Morning blisters: cantharidin-related Meloidae burns. We report several cases of Meloidae-related blisters in French soldiers deployed to Mali. Blister beetles of the Meloidae family produce cantharidin, a blistering agent, for defensive purposes. These virtually cosmopolitan Coleoptera can cause significant nuisance to travellers and deployed soldiers especially during the rainy season in the Sahel region.

2018 Journal of Travel Medicine

13. Multiple Arterial Thrombosis Related with Cantharidin Ingestion (PubMed)

Multiple Arterial Thrombosis Related with Cantharidin Ingestion Inherited and/or acquired thrombophilic defects can result in venous or arterial thrombosis. This case report describes arterial thrombotic episodes triggered by the ingestion of an aphrodisiac remedy containing cantharidin in a 46-year-old female patient later discovered to be heterozygous for prothrombin G20210A mutation and seropositive for anti-β2 glycoprotein-I (anti-β2-GPI) antibodies of IgA isotype.

Full Text available with Trip Pro

2018 Case reports in hematology

14. Cantharidin suppresses cell growth and migration, and activates autophagy in human non-small cell lung cancer cells (PubMed)

Cantharidin suppresses cell growth and migration, and activates autophagy in human non-small cell lung cancer cells Cantharidin (CTD), a component of Mylabris (blister beetle), is a traditional Chinese medicine that exerts an anticancer effect in multiple types of cancer cells. The aim of the present study was to investigate whether CTD exhibited anti-metastatic and inhibitory cell proliferation effects against human non-small cell lung cancer (NSCLC) A549 cells, and the possible underlying

Full Text available with Trip Pro

2018 Oncology letters

15. The combination of cantharidin and antiangiogenic therapeutics presents additive antitumor effects against pancreatic cancer (PubMed)

The combination of cantharidin and antiangiogenic therapeutics presents additive antitumor effects against pancreatic cancer Cantharidin, one of the active components of mylabris, is believed to have antitumor activity. Cantharidin selectively inhibits protein phosphatase 2A (PP2A), which can repress multiple oncogenic kinases (ERK, JNK, PKC, and NF-κB). Researches in vitro have shown that cantharidin suppresses cell viability and metastasis in pancreatic cancer cells. This study aims (...) to investigate the effects of cantharidin on pancreatic cancer xenografts in vivo. Xenograft models were established using cells stably expressing luciferase. Xenograft growth was evaluated by living imaging. Gene expression was determined using a microarray, real-time PCR, a RayBiotech antibody array, and the Milliplex assay. Surprisingly, cantharidin significantly accelerated xenograft growth. Living imaging showed a rapid distribution of D-luciferin in cantharidin-treated xenografts, suggesting a rich

Full Text available with Trip Pro

2018 Oncogenesis

16. Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2

Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2 Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2 - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2 The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03017846 Recruitment Status : Completed First Posted : January 11, 2017 Results First Posted : January 30, 2019 Last Update

2017 Clinical Trials

17. Cantharidin Induced Oral Squamous Cell Carcinoma Cell Apoptosis via the JNK-Regulated Mitochondria and Endoplasmic Reticulum Stress-Related Signaling Pathways. (PubMed)

Cantharidin Induced Oral Squamous Cell Carcinoma Cell Apoptosis via the JNK-Regulated Mitochondria and Endoplasmic Reticulum Stress-Related Signaling Pathways. Oral cancer is a subtype of head and neck cancer which represents 2.65% of all human malignancies. Most of oral cancer is histopathologically diagnosed as oral squamous cell carcinoma (OSCC). OSCC is characterized by a high degree of local invasion and a high rate of metastasis to the cervical lymph nodes. How to prevention and treatment (...) of OSCC is important and imperative. Here, we investigated the therapeutic effect and molecular mechanism of cantharidin, an active compound isolated from blister beetles, on OSCC in vitro. Results showed that cantharidin significantly decreased cell viability in human tongue squamous carcinoma-derived SAS, CAL-27, and SCC-4 cell lines. The further mechanistic studies were carried out in SAS cells. Cantharidin also significantly increased apoptosis-related signals, including caspase-9, caspase-7

Full Text available with Trip Pro

2016 PLoS ONE

18. Cantharidin Application in Molluscum Patients

Cantharidin Application in Molluscum Patients Cantharidin Application in Molluscum Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Cantharidin Application in Molluscum Patients (CAMP-2) The safety (...) -Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum Actual Study Start Date : February 14, 2018 Estimated Primary Completion Date : September 28, 2018 Estimated Study Completion Date : September 28, 2018 Arms and Interventions Go to Arm Intervention/treatment Active Comparator: VP-102 VP-102 Film Forming Solution applied via a prefilled applicator to affected area every 21

2017 Clinical Trials

19. Cantharidin Application in Molluscum Patients-1

Cantharidin Application in Molluscum Patients-1 Cantharidin Application in Molluscum Patients-1 - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Cantharidin Application in Molluscum Patients-1 (CAMP-1 (...) -Controlled, Pivotal Study to Evaluate the Safety and Efficacy of VP-102 Topical Film-Forming Solution [0.7% (w/v) Cantharidin] in Subjects (2 Years and Older) With Molluscum Contagiosum Actual Study Start Date : March 21, 2018 Estimated Primary Completion Date : November 19, 2018 Estimated Study Completion Date : November 19, 2018 Arms and Interventions Go to Arm Intervention/treatment Active Comparator: VP-102 VP-102 Film Forming Solution applied via a prefilled applicator to affected area every 21 days

2017 Clinical Trials

20. Effects of disodium cantharidinate on dendritic cells of patients with bladder carcinoma (PubMed)

Effects of disodium cantharidinate on dendritic cells of patients with bladder carcinoma The present study explored the effects of disodium cantharidinate (DC) on the peripheral blood-derived dendritic cells of patients with bladder carcinoma. The peripheral blood mononuclear cells from the 15 cases of urinary bladder carcinoma of middle and advanced stage were separated, and dendritic cells were prepared. The morphological changes of dendritic cells were observed. Flow cytometry was used

Full Text available with Trip Pro

2017 Oncology letters

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>